Voyager Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $10.1M | $14.2M | $17.3M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $62.3M | $42.2M | $27.7M |
| SG&A Expense | $19.7M | $13.3M | $9.9M |
| Operating Income | $-71.9M | $-41.3M | $-20.3M |
| Operating Margin | -709.1% | -290.4% | -116.8% |
| Interest Expense | — | — | — |
| Pretax Income | $-70.7M | $-40.1M | $-29.7M |
| Income Tax Expense | — | $52.0K | $0 |
| Net Income | $-70.7M | $-40.2M | $-29.7M |
| Net Margin | -697.6% | -282.7% | -171.2% |
| EPS (Basic) | $-2.64 | $-1.59 | $9.14 |
| EPS (Diluted) | $-2.64 | $-1.59 | $9.14 |
| Shares Outstanding (Basic) | 31.6M | 25.6M | 24.9M |
| Shares Outstanding (Diluted) | 31.6M | 25.6M | 24.9M |
| Dividends Per Share | — | — | $0.00 |